Every piece MicroCap Desk has published on Biomea Fusion, newest first. Independent editorial — we take no compensation from the companies we cover.
Biomea showed icovamenib diabetes data at ADA and is advancing BMF-650, with an obesity readout due in Q3.
Why covalent, irreversible small-molecule binding is having a quiet renaissance.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.